Molecular Analysis for Precision Surgery in Thyroid Cancer Trial
About
Ideal surgical extent for differentiated thyroid cancer remains unclear. Routine use of molecular analysis in biopsy-proven thyroid cancer could provide important prognostic information to help guide extent of surgery - thyroid lobectomy versus total thyroidectomy. This is a pilot feasibility study for the use of routine molecular analysis in Bethesda V and VI thyroid cancers, with randomization of the intermediate-molecular risk subgroup to thyroid lobectomy and total thyroidectomy. The investigators hypothesize that patients will 1) agree to preoperative molecular analysis, and 2) 50% of intermediate-risk patients will agree to and follow through with randomization. This will be a pilot study for a future randomized controlled trial (RTC) to compare between the two surgical approaches in intermediate-molecular risk thyroid cancer.
Eligibility
Inclusion Criteria:
- Patients aged 18 years or older at the time of enrollment
- English-speaking
- Bethesda V or VI thyroid nodule that are 1-4cm in size
- Bethesda III or IV nodules who underwent previously underwent Thyroseq molecular analysis that returned with intermediate molecular risk disease
Exclusion Criteria:
- Prior thyroid operation
- Extrathyroidal extension or lymph node metastases seen on ultrasound
- Distant metastatic disease
Join this Trial
- UCLA Westwood